Showing 2801-2810 of 9838 results for "".
Exploring the Benefits of Nitric Oxide for Hair Loss Patients Through REVIAN® Red
https://practicaldermatology.com/topics/hair-nails/exploring-the-benefits-of-nitric-oxide-for-hair-loss-patients-through-revian-red/19753/Learn more about the mechanism of action of the new REVIAN Red Dual-Band LED light therapy cap and what makes it unique from other at-home FDA-cleared devices. REVIAN Red is indicated to treat androgenetic alopecia and to promote hair growth in males who have Norwood-Hamilton classifications of IIaOrchiectomy-Induced Melasma: Considering Melasma in Male Patients Post-Orchiectomy
https://practicaldermatology.com/topics/clinical-case-reports/orchiectomy-induced-melasma-considering-melasma-male-patients-post-orchiectomy/26663/Orchiectomy-Induced Melasma: Considering Melasma in Male Patients Post-OrchiectomyDermWireTV: Meet Crown Aesthetics, Revance to Market Teoxane Fillers, Almirall Collaborates
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-meet-crown-aesthetics-revance-to-market-teoxane-fillers-almirall-collaborates/19719/On the heels of recent acquisitions, Crown Laboratories is reorganizing and rebranding as three divisions: Crown Aesthetics, Crown Beauty, and Crown Therapeutics. Revance gains immediate and exclusive rights to commercialize Teoxane’s RHA 2, RHA 3, and RHA 4 products, which include lidocaine. A fourRepresentation in Marketing and Outreach
https://practicaldermatology.com/series/diversity-and-equity-in-dermatology/representation-in-marketing-and-outreach/19916/There is an apparent low rate of participation in aesthetic procedures among patients of color. Does this reflect a lack of interest or does limited representation in marketing and educational materials leave patients feeling that aesthetic interventions aren't meant for them? Panelists discuss theGalderma, Allergan Rosacea News, Dupilumab Data
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-galderma-allergan-rosacea-news-dupilumab-data/18591/Galderma Laboratories launched a new pump dispenser design for Mirvaso (brimonidine) Topical Gel, 0.33. The FDA has accepted Allergan's New Drug Application (NDA) filing for oxymetazoline cream 1.0%, an investigational topical prescription product for the treatment of persistent facial erythema asso2020 Financial Benchmark Report: How Dermatology and Aesthetic Practices Fared in the COVID Era
https://practicaldermatology.com/topics/practice-management/2020-financial-benchmark-report-how-dermatology-and-aesthetic-practices-fared-in-the-covid-era/23693/How did your practice’s performance and growth compare to the rest of the industry?Hydroquinone in 2021
https://practicaldermatology.com/topics/pigmentary-disorders/hydroquinone-in-2021/23592/A year after OTC hydroquinone was pulled from the market as part of the CARES Act, a dermatologist discusses the effects on patient care.Optimizing Absorption of Oral Isotretinoin
https://practicaldermatology.com/columns/clinical-focus-1/optimizing-absorption-of-oral-isotretinoin/23066/An update on lidose-isotretinoin and the ability to enhance absorption in the absence of high-fat meals.JAK Inhibitors in Vitiligo Treatment
https://practicaldermatology.com/series/updates-vitiligo/jak-inhibitors-vitiligo-treatment/24559/Dr. Ted Lain, a dermatologist practicing in Austin, Texas, talks with Practical Dermatology about the latest developments and the promise of Janus kinase (JAK) inhibitors for the treatment of vitiligo. Dr. Lain covers the current impact of JAK inhibitors, their mechanism of action, how he's using thDonate Against East Coast Bias
https://practicaldermatology.com/columns/editors-message/donate-against-east-coast-bias/23944/